ABSTRACT
B Cells Transduced with HPV16 E6/E7-expressing Adenoviral Vector Can Efficiently Induce CTL-dependent Anti-Tumor Immunity
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Introduction
High-risk human papillomavirus (HPV) infection, particularly by HPV16, is responsible for development of cervical cancer (1) (2) (3) (4) . The importance of the immune system in controlling HPV infection and preventing cancer development can be deduced from the increased incidence of persistent infection and progression to cervical cancer in patients whose immune system is defective. Moreover, humoral and cellular immune responses against HPV were detected in patients whose pre-cancerous lesions spontaneously regressed (5, 6) . Therefore, immunotherapy, which potentiates host immune responses against HPV, can be helpful in preventing or treating HPV-associated cervical cancer. Previous reports have demonstrated that immunotherapy using HPV viral antigens can elicit anti-tumor immunity against HPV-related tumors in animal models (7) (8) (9) (10) (11) .
Prophylactic vaccines using the HPV structural proteins L1 and/or L2 have been developed and approved by the FDA (2, 4) . However, because L1 and L2 are not expressed in cervical cancer, vaccines using them cannot be expected to have any therapeutic effect and have indeed been used only in those who have not been exposed to HPV. A great need still exists for the development of more effective prophylactic and therapeutic vaccines for HPV-associated cervical cancer. Two oncoproteins of HPV, E6 and E7, offer potential targets for cancer immunotherapy, because they are constitutively expressed in cervical cancer and cause cellular transformation, as well as maintain malignant phenotype (2) .
Cellular vaccines using antigen-presenting cells (APC) such as dendritic cells (DCs) efficiently activate antigen-specific CD8 + and CD4 + T cells (12) . Dendritic cells are able to stimulate diverse effector cells by capturing, processing, and presenting antigens with co-stimulatory signals (13) . Despite the strong immunogenicity of DCs, obstacles exist to the clinical development of DC vaccines, namely the difficulty in obtaining large numbers of DCs in a homogeneous state (14) . Thus, alternative APCs should be considered as potential sources of cellular vaccines. B cells offer an attractive alternative in that large numbers of them can be obtained from a small volume of blood with high purity (14, 15) . Although poorly immunogenic and tending to induce T cell tolerance due to lack of co-stimulation (16) (17) (18) , activated B cells have been reported by several groups to generate antigen-specific immune responses by priming both CD4 + and CD8 + T cells (19) (20) (21) (22) . Recombinant adenoviral vectors can be used to transduce tumor antigens into APCs because they are able to infect both resting and proliferating cells and to induce both humoral and cellular immune responses (23, 24) . Moreover, adenovirus transduction in itself could induce DC differentiation and maturation (25, 26) .
In an effort to develop more efficient vaccines for the prevention and treatment of HPV-associated cervical cancer, we generated B cell vaccine by transducing B cells with adenovirus expressing HPV16 E6/E7 (AdE6E7). This B cell vaccine induced E6/E7-specific cell-mediated immune responses and anti-tumor effects against E6/E7-producing TC-1 tumors as efficiently as did DC vaccines.
Materials and Methods
Mice. Female C57BL/6 mice (The Charles River, Seoul, Korea) were purchased and kept under specific patho- Biogene) as described earlier (27) . Briefly, the complementary DNA of E6E7 was sub-cloned into the Kpn I/Xba I sites of the adenoviral shuttle vector (pShuttleCMV). pShuttleCMV/E6E7 construct was cotransformed with adenoviral backbone vector, pAdEasy, into Escherichia coli BJ5183 by electroporation to achieve homologous recombination. The recombinant obtained was transfected into 293 cells by the conventional calcium phosphate co-precipitation method. Recombinant adenovirus was isolated from a single plaque, expanded in 293 cells, and purified by double cesium chloride ultracentrifugation. Purified viruses were extensively dialyzed against 10 mM Tris, 5% sucrose, 2 mM MgCl 2 and stored in aliquots at -80 o C.
Titer of adenovirus was determined by Tissue culture infectious dose 50 (TCID 50 ) and by plaque assays in 293 cells. Generation of B cell and DC vaccines. B cells were magnetically isolated from spleen using anti-B220 microbeads (Miltenyi Biotec, USA), Dendritic cells were generated by culturing bone marrow cells in media containing GM-CSF (20ng/ml) for 6 days. B cells and DCs were transduced with 100 multiplicity of infection (MOI) of AdE6E7 for 24 hours.
RT-PCR. Total RNAs from B/AdE6E7 and DC/ AdE6E7 were extracted with trizol. Reverse transcription was performed with 1.2μg of RNAs, and PCR was run with 5μl of the cDNA using the E7-specific primer (F5'-ACGAGTACATGCTGGATCTG-3', R5'-GATGTCTACGTGGGTGCTCT-3 , a protein transport inhibitor (BD biosciences, USA), was added for the last 6 hours. Stimulated cells were stained with PE-labeled anti-CD8 and APC-labeled anti-IFN-γ and analyzed using flow cytometry. Statistical analysis. The Student t test was used to compare the differences between the two groups using SPSS (SPSS, Chicago, Illinois). Values of p＜0.05 were considered significant at a 95% confidence interval.
Results

Generation of B cell vaccine.
To make B cell vaccine, we isolated resting B cells from spleen using anti-B220 beads and analyzed surface molecules using flow cytometry. The B cells were CD19-positive (＞99%) and expressed high levels of MHC class II, intermediate levels of CD86 and CD40 and low levels of CD80 (Fig. 1A) . The expression level of these surface molecules were not changed after transduction with E6/E7-expressing adenovirus (AdE6E7), at least within 24 hours (data not shown). To confirm antigen expression after AdE6E7 transduction, we performed RT-PCR using E7-specific primers. We detected the expression of HPV16 E7 on AdE6E7-transduced B cells, although the expression level was relatively low compared to that of AdE6E7-transduced DCs (Fig.  1B) . tumor cells. The anti-tumor immunity elicited by B/AdE6E7 was so potent that no tumor growth was seen (Fig. 3) . The tumor mass remained impalpable until the end of the experiment.
E7-specific CD8 + T cell responses are induced by B/AdE6E7
vaccination. To better understand how B/AdE6E7 vaccination elicited anti-tumor effects against TC-1 tu- mor, we evaluated antigen-specific immune responses. Because E6 and E7 are cytoplasmic proteins, MHC class I-dependent CD8 + T cell responses are known to be important in eliminating E6/E7-producing cells (28) . Therefore we assessed CD8 + T cell dependent-immune responses. Splenocytes from vaccinated mice were cultured in vitro with irradiated TC-1 cells for 6 days to restimulate CTLs. Stimulated splenocytes were then harvested and CTL activity was determined using a Cr-51 release assay (Fig. 4) . Splenocytes from B/AdE 6E7-immunized mice lysed TC-1 tumor cells (41.0%±9.3% at E:T ratio of 10:1). The cytotoxicity induced by B/AdE6E7 vaccination was weaker than that induced by DC/AdE6E7 vaccination (72.9% ±9.6% at E:T ratio of 10:1). IFN-γ production was also assessed using an intracellular cytokine staining (ICS) assay (Fig. 5) . Spleen cells were stimulated with MHC class I -restricted peptide (E7 [49] [50] [51] [52] [53] [54] [55] [56] [57] 
Discussion
Human papillomavirus infection is the main cause of cervical cancer, a common cancer in women (1-3). Immune defects have been shown to lead to persistent infection and progression to cervical cancer. Therefore, immunotherapy to potentiate the host immune system against HPV can be effective for preventing and treating HPV-associated cervical cancer (2, 4) . Although prophylactic vaccines have been developed using the viral capsid proteins L1 and/or L2, their application is restricted to non-HPV-exposed people. Because these proteins are absent in cervical cancer, no therapeutic effect can be expected. In contrast, E6 and E7, HPV viral oncoproteins, are constitutively expressed in precancerous lesions and cervical cancer and so are well known to be promising targets for HPV vaccines (2, 4, (7) (8) (9) (10) .
To develop an efficient cellular vaccine against HPV16 E6/E7, we used B cells as APCs. Although B cells have been regarded as poorly immunogenic APCs (16) (17) (18) , activated B cells have been shown to act as immunogenic APCs capable of inducing antigen-specific immune responses (19) (20) (21) (22) . We generated B cell vaccines by transducing B cells with HPV16 E6/ E7-expressing adenovirus (B/AdE6E7). By using an adenoviral vector encoding full-length antigen as an antigen-delivery tool, we were able to overcome the problems related to HLA restriction and occurrence of tumor antigen variants. We also expect to achieve diverse immunities against multiple epitopes.
We observed that vaccination with B/AdE6E7 activated CD8 + T cells to secrete IFN-γ, induced CTL activity, and finally elicited anti-tumor effects against E6/E7-expressing TC-1 tumor. We also found that although CD8 + T cells are the major effector cells for the elimination of TC-1 tumor cells, CD4 + T cell help is necessary to elicit efficient therapeutic effect. As shown in Figure 6 , delayed anti-tumor effects were observed when CD4 + T cells were depleted. However, even in the absence of CD4 + help, B/AdE6E7 is able to elicit anti-tumor effects. Therefore, we assume that B/AdE6E7 vaccination may be effective in AIDS patients and transplant recipients who are at high risk of developing HPV-associated cervical cancer because of low levels of CD4 + T cells (29) .
We compared the immune response and anti-tumor effects induced by the B cell vaccine with those induced by DC vaccines, which have generally been used for cellular vaccines (12, 13) . Immunization with B/ AdE6E7 induced weaker immune responses against HPV16 E6/E7 than did DC/AdE6E7. These results may reflect the small size, the low antigen-expression level and the weak co-stimulatory signal of B cells compared to DCs. Although B/AdE6E7 generated weaker antigen-specific immune responses than DC/ AdE6E7, the anti-tumor effect elicited by B/AdE6E7 was sufficient to eradicate E6/E7-producing TC-1 tumor as effectively as DC/AdE6E7.
Moreover, the B cell vaccine offers a number of clear advantages over DC vaccines for clinical application: 1) large numbers of highly pure B cells can be obtained from a small volume of blood; 2) the process for generating B cell vaccines is relatively simple, consisting of only two steps, i.e., purification of B cells from blood and transduction with adenovirus; and 3) B cell vaccines require less time and expense to produce than DC vaccines. In contrast, DCs, which are differentiated from precursor cells, require periods of culture with cytokines.
Further studies are necessary to improve the anti-tumor effect of the B cell vaccine and to test its efficacy in clinical trials. One method for enhancing the anti-tumor effect of the B cell vaccine is the use of a bicistronic adenoviral vector co-expressing antigen and a cytokine such as IL-12 that potentiates anti-tumor immunity (7, 30) . Enhancement of the co-stimulatory signal can also augment the immunogenicity of B cells. Hence, CD40 ligation has been used to activate B cells and to enhance their antigen-presentation capacities (19) (20) (21) . The activation of B cells with NKT cell help could help induce antigen-specific cytotoxic anti-tumor immunity (22) .
In summary, our study has shown the feasibility of using B cells as immunogenic APCs and the potential for developing prophylactic and therapeutic vaccines against HPV-associated cervical cancer using a B cell vaccine transduced with adenovirus expressing HPV16 E6/E7. The B/AdE6E7 vaccine could be more easily, inexpensively, and quickly produced than DC vaccines and should be ready for clinical application in the near future.
